For example, CRC patients with KRAS, NRAS, or BRAF mutations do not benefit from anti-epidermal growth factor receptor (EGFR) therapies such as cetuximab or panitumumab [20–23]. The gene discussed is KRAS; the disease is colorectal carcinoma.